Ozempic and Wegovy may raise hair loss risk in some men
A study from NYU Langone Health suggests that men with a genetic predisposition to hair loss may face an increased risk of shedding when using GLP-1 receptor agonist drugs like Ozempic and Wegovy. Researchers believe these medications may interact with the GLP1R gene, which is linked to androgenetic alopecia.
Why it matters
As the popularity of weight-loss drugs grows, understanding potential side effects is crucial for patients and doctors managing long-term treatment plans.
Men who are already genetically predisposed to the most common type of hair loss may face an additional 7 percent risk of losing hair when using drugs such as Ozempic, Wegovy, and Zepbound for type 2 diabetes and obesity, according to a new study.
Researchers at NYU Langone Health examined the GLP1R gene, which naturally influences levels of glucagon-like peptide-1 (GLP-1) receptor proteins in the body. They used activity involving this gene as an indicator of GLP-1 agonist activity. Greater GLP1R activity is associated with higher levels of GLP-1 receptor proteins.
Get smarter about the news
Sign up free for a feed built around what you actually care about, Dive Deeper research on any story, and the full text of every article.
Create free accountAlready have an account? Sign in